GlaxoSmithKline CEO Andrew Witty attributes the company’s success to sticking to the tried-and-true business model of investing in research and development and not transitioning to an acquisition model.
Witty told CNBC’s “Closing Bell” on Monday that the key is to be patient and to see the value of investing in innovation.
“What we have to stay focused on is the fundamentals of the value of innovation and discovery of medicines and vaccines that make a real difference to patients,” he said.
“We’ve been criticized by people at times for not being exciting enough in terms of embracing the new ideas of how to quickly move things forward. I think the reality of what we’ve seen is there aren’t any shortcuts,” Witty said.
The alternative acquisition model in the health care industry has drawn criticism during this election year. In theory, the M&A strategy can save companies significant sums as they can purchase mature, fully developed products without having to invest in R&D.
“We’ve turned our face away from some of the more novel business model approaches, which often times look interesting in the short run but don’t have legs in the long run,” Whitty said.
Looking forward, GSK wants to continue to innovate and replace their pipeline as older drugs go generic, a process that pressures the revenue streams of pharmaceutical companies.
“Over the last five or six years, we’ve successfully organically replaced about 60 percent of the revenue we had which has gone off patent … That pressure has been on, but we’re coming through that,” Whitty said.
By Christine Wang
Source: CNBC
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.
